Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 6;10(1):7625.
doi: 10.1038/s41598-020-63652-x.

Effect of commercial vaginal products on the growth of uropathogenic and commensal vaginal bacteria

Affiliations

Effect of commercial vaginal products on the growth of uropathogenic and commensal vaginal bacteria

Kristin J Hung et al. Sci Rep. .

Abstract

Half of postmenopausal women experience genitourinary syndrome of menopause, for which many use lubricating vaginal products. The effect of vaginal products on uropathogenic and commensal vaginal bacteria is poorly understood. We evaluated the effect of five common vaginal products (KY Jelly, Replens Silky Smooth lubricant, coconut oil, Replens Long-Lasting moisturizer or Trimo-San) on growth and viability of Escherichia coli and Lactobacillus crispatus. Bacteria were co-cultured products alone and in the presence of both vaginal epithelial cells and selected products. Bacterial growth was compared between conditions using an unpaired t-test or ANOVA, as appropriate. All products except for coconut oil significantly inhibited growth of laboratory and clinical strains of Escherichia coli (p < 0.02). Only two products (Replens Long-Lasting moisturizer and Trimo-San) significantly inhibited growth of Lactobacillus crispatus (p < 0.01), while the product Replens Silky Smooth stimulated growth (p < 0.01). Co-culture of selected products in the presence of vaginal epithelial cells eliminated the inhibitory effects of the products on E. coli. In conclusion, in vitro exposure to vaginal moisturizing and lubricating products inhibited growth of Escherichia coli, though the inhibition was mitigated by the presence of vaginal epithelial cells. Lactobacillus crispatus demonstrated less growth inhibition than Escherichia coli.

PubMed Disclaimer

Conflict of interest statement

Dr. Mitchell has served as a consultant for Lupin Pharmaceuticals and Scynexis, Inc. Dr. Mitchell receives research funding from Merck. The remaining authors declare they have no conflict of interest.

Figures

Figure 1
Figure 1
Change in bacterial growth with exposure to vaginal products. (a) Final change in growth, as measured by OD600, for laboratory strain of E. coli is similar to that for representative strain (F) of clinical E. coli across all test conditions (p > 0.05). (b) Final change in growth of L. crispatus, as measured in CFU (simple co-culture, without vaginal epithelial cells), demonstrating inhibition by Replens Long-Lasting moisturizer and Trimo-San (p < 0.01). L. crispatus growth was stimulated by Replens Silky Smooth (p < 0.01). As expected, methylparaben killed L. crispatus (p < 0.01), and lactic acid did not have a significant effect compared with control.
Figure 2
Figure 2
Change in bacterial growth with exposure to vaginal products in the presence of vaginal cells. (a) Final change in growth of E. coli, as measured in CFU (in 1:100 diluted product and KSF cell culture media as control), in the absence and presence of vaginal epithelial cells, demonstrating growth in Trimo-San and Replens Long-Lasting moisturizer in the presence of human cells (p < 0.05). (b) Final change in growth of L. crispatus, as measured in CFU (in 1:100 diluted product and MRS/KSF cell culture media as control), demonstrating a lack of inhibition by KY Jelly, Replens Long-Lasting moisturizer and Trimo-San, regardless of the presence of human vaginal epithelial cells (p > 0.05).

Similar articles

Cited by

References

    1. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon. 2003;49:53–70. doi: 10.1067/mda.2003.7. - DOI - PubMed
    1. Guglietta A. Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiol. 2017;12:239–246. doi: 10.2217/fmb-2016-0145. - DOI - PubMed
    1. den Heijer CD, Beerepoot MA, Prins JM, Geerlings SE, Stobberingh EE. Determinants of antimicrobial resistance in Escherichia coli strains isolated from faeces and urine of women with recurrent urinary tract infections. PLoS One. 2012;7:e49909. doi: 10.1371/journal.pone.0049909. - DOI - PMC - PubMed
    1. Schwenger, E. M., Tejani, A. M. & Loewen, P. S. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev, CD008772, 10.1002/14651858.CD008772.pub2 (2015). - PMC - PubMed
    1. Hooton TM, Roberts PL, Cox ME, Stapleton AE. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013;369:1883–1891. doi: 10.1056/NEJMoa1302186. - DOI - PMC - PubMed

Publication types

MeSH terms